Ignite Creation Date:
2024-05-06 @ 4:15 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04923048
Status:
RECRUITING
Last Update Posted:
2023-05-22
First Post:
2021-06-04
Brief Title:
A Safety Tolerability Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL
Sponsor:
Genor Biopharma Co Ltd
Organization:
Genor Biopharma Co Ltd
Study Overview
Official Title:
A Phase ⅠⅡ Open-Label Multicenter Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of GB261 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Status:
RECRUITING
Status Verified Date:
2022-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 12 study of GB261 in participants with relapsed or refractory B-cell NHL and CLL The study will consist of a dose-escalation stagePhase 1 an expansion stagePhase 2a and Phase 2b stage where participants will be enrolled into indication-specific cohorts
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None